Integrating endometrial proteomic and single cell transcriptomic pipelines reveals distinct menstrual cycle and endometriosis-associated molecular profiles

Summary

Endometriosis is a debilitating gynecological disorder affecting approximately 10% of the female population. Despite its prevalence, robust methods to classify and treat endometriosis remain elusive. Changes throughout the menstrual cycle in tissue size, architecture, cellular composition, and individual cell phenotypes make it extraordinarily challenging to identify markers or cell types associated with uterine pathologies since disease-state alterations in gene and protein expression are convoluted with cycle phase variations. Here, we developed an integrated workflow to generate both proteomic and single-cell RNA-sequencing (scRNA-seq) data sets using tissues and cells isolated from the uteri of control and endometriotic donors. Using a linear mixed effect model (LMM), we identified proteins associated with cycle stage and disease, revealing a set of genes that drive separation across these two biological variables. Further, we analyzed our scRNA-seq data to identify cell types expressing cycle and disease- associated genes identified in our proteomic data. A module scoring approach was used to identify cell types driving the enrichment of certain biological pathways, revealing several pathways of interest across different cell subpopulations. Finally, we identified ligand-receptor pairs including Axl/Tyro3 – Gas6, that may modulate interactions between endometrial macrophages and/or endometrial stromal/epithelial cells. Analysis of these signaling pathways in an independent cohort of endometrial biopsies revealed a significant decrease in Tyro3 expression in patients with endometriosis compared to controls, both transcriptionally and through histological staining. This measured decrease in Tryo3 in patients with disease could serve as a novel diagnostic biomarker or treatment avenue for patients with endometriosis. Taken together, this integrated approach provides a framework for integrating LMMs, proteomic and RNA-seq data to deconvolve the complexities of complex uterine diseases and identify novel genes and pathways underlying endometriosis.

• Download figure
• Open in new tab

Highlights

• Leverages proteomic data to interpret and direct single-cell RNA sequencing (scRNA- seq) analysis

• Demonstrates successful use of linear mixed effects models to attribute protein expression variance to either menstrual cycle phase or disease state

• Pathway analysis of disease state proteins guides identification of disease-relevant cell types present in scRNA-seq data, providing foundation for mining those data for receptor-ligand interactions of possible disease relevance

• A new potential non-hormonal target in endometriosis, TYRO3, emerges from confirming predictions of the receptor-ligand model with transcriptomic and immunohistochemistry analysis of an independent panel of endometrial biopsies

Competing Interest Statement

B.A.G. reports compensation for consulting for FL82, unrelated to this work. A.K.S. reports compensation for consulting and/or SAB membership from Merck, Honeycomb Biotechnologies, Cellarity, Repertoire Immune Medicines, Ochre Bio, Third Rock Ventures, Hovione, Relation Therapeutics Limitied, Empress Therapeutics, FL82, and Dahlia Biosciences, unrelated to this work.

Funding Statement

This work was supported in part by NIH U01 EB029132, NIH P30-ES002109, NRSA postdoctoral fellowship (F32-AI136459, Goods), NIH Toxicology Training Grant (T32ES007020, L.M.B), the John and Karine Begg Fund, the Endometriosis Association of America, and The Manton Foundation, as well as a Sloan Fellowship in Chemistry (A.K.S.). C.N.T. is funded by fellowships from the Fannie and John Hertz Foundation and the National Science Foundation (NSF) Graduate Research Fellowship Program (1122374).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

IRBs of MassGeneralBrigham and the Massachusetts Institute of Technology gave ethical approval for this work.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes